CCHF is a serious viral disease with no approved vaccines or treatments. A new mouse study in npj Vaccines, led by a team that includes Scott Pegan at UC Riverside, tested an experimental vaccine. The vaccine uses a harmless virus-like replicon particle that can enter cells but cannot replicate because it lacks the virus genetic material.
The team had shown earlier that one dose could protect animals within three days. In the new work researchers measured antibodies after one or two doses. Antibodies remained detectable for up to 18 months, roughly like several years in humans. A booster produced stronger, more stable antibodies and longer protection. Next steps include large-scale production under Good Manufacturing Practice before human trials, and partners at the CDC are exploring the same platform for other viruses.
Difficult words
- experimental — not fully tested; a new treatment in tests
- replicon — a small virus-like particle used in research
- replicate — to make a copy of itself
- antibody — a blood protein that fights infectionAntibodies
- booster — an extra dose of a vaccine
- detectable — can be found or measured
- protection — the state of being safe from disease
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Do you think it is important to test vaccines in animals before people? Why?
- Would you take a booster if it gave longer protection? Why or why not?
- What information would you want before human trials begin?
Related articles
Study: Industrial Revolution pollution affected people unevenly in England
A study in Science Advances used bones and historical records to track pollution exposure during the Industrial Revolution. Researchers analysed remains from 94 people in industrial South Shields and rural Barton-upon-Humber and found uneven, gendered exposure.
Sudan turns to AI as health system struggles
Sudan’s health system is under severe strain after an almost two‑year civil war. A senior health official says the country is using artificial intelligence to help provide care where normal services no longer reach, while shortages and attacks worsen the crisis.
Engineered antibodies could block cytomegalovirus
A research team created changed antibodies that stop human cytomegalovirus from disabling immune responses. Lab tests show the antibodies reduce virus spread, but researchers say more testing is needed before they can be used in people.
Gene Variant Raises Heart Failure Risk After Myocarditis in Children
A study found that a cardiomyopathy gene variant is more common in children who develop dilated cardiomyopathy after myocarditis. Researchers describe a "double hit" model and advise genetic testing to identify higher risk.
